The treatment of IGF‐2‐mediated hypoglycaemia can be divided into two phases: acute management, which can be similar to hypoglycaemia of other causes, and definitive treatment by focusing on reduction in tumour function. This evidence concerns the gene IGF2 and neoplasm.